Surgery News
-
Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline
Thomas Englese, a 20+ year industry veteran with a track record of success at leading biopharmaceutical companies, joins as chief commercial officer Marc Lesnick, Ph.D., appointed as chief development officer, bringing more than 20 years of experience in multiple therapeutic areas Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological ...
-
CanaQuest and Neeka Health Sign Agreement to Conduct Clinical Studies with Mentanine
Canaquest Medical Corp (OTC:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced the signing of a Master Service Agreement with Neeka Health (“Neeka”) that will encompass multiple clinical studies to evaluate the ...
-
CO2 fractional laser treatment facial skin problems
Acne, pigmentation and wrinkles are the three major facial skin problems that plague many women. Many women have thus become people who do not go out without make-up, for no other reason than the large pores on their faces and pore pockmarks that are more visible than in boys. CO2 fractional laser treatment for facial skin problems is highly effective. Bvlaser Bestview is a professional CO2 ...
-
How to deal with the trend of population aging to achieve a sustainable future
The World Social Report 2023 calls for concrete measures to support an aging global population in the face of rising pension and health care costs. According to a study published by the United Nations Department of Economic and Social Affairs, population aging is the defining global trend of our time. Countries can benefit by promoting equality of opportunity from birth, so that everyone has the ...
-
With Policy Support, the Market for Surgical Robots Grows
Recently, the Ministry of Industry and Information Technology, the National Health Commission and other 17 departments jointly issued the "robot" application action implementation plan to encourage the development of surgery, auxiliary examination, auxiliary rounds, intensive care, rehabilitation and other medical robot products, "robot The "robot" has ushered in a new round of development ...
-
CO2 fractional laser in cosmetic dermatology
The best CO2 fractional laser machine is a common cosmetic treatment, commonly used for skin treatment such as mole removal, flat warts, acne pit scars, etc. It can also be used for facial rejuvenation such as wrinkle removal, etc. CO2 laser skin resurfacing machine is a minimally invasive laser treatment technique. Traditional CO2 laser treatment has a long recovery period and greater damage, ...
-
Effectiveness of the picosecond laser and the precautions after treatment
Picosecond is actually short for picosecond laser. A picosecond is a unit of time equivalent to one ten trillionth of a second. Picosecond laser tattoo removal machine has a wide range of applications in dermatological treatments and are used in cosmetic equipment. Picosecond laser device can remove spots, acne marks, melanin, remove tattoos, rejuvenate skin and shrink pores, among other effects. ...
-
Press release: High quality, cost effective surgical retractor is welcomed by leading US hospital group
JUNE Medical is delighted to announce a new agreement with a major US hospital group to supply the award-winning Galaxy II® self-retaining surgical retractors to over 1,600 hospitals in the US, commencing April 15, 2023. This game-changing device radically improves the safety and ease of surgical retraction for both patients and medical staff; its ergonomic design transforms the way in which ...
-
Is the CO2 fractional laser damaging to the skin
The best fractional CO2 laser machine is a minimally invasive treatment. It works by heating the dermis and epidermis with a fractional laser, causing microscopic columnar damage to the skin, activating fibroblasts, stimulating collagen remodelling reactions, thickening the dermis and achieving cosmetic results such as wrinkle reduction, skin rejuvenation and spot removal. Today the CO2 laser ...
-
Is HIFU ultrasound treatment safe
Ultrasound HIFU beauty machine is a non-surgical skin tightening treatment, that uses medical aesthetic focused ultrasound technology to bypass the epidermis and heat the energy to 65-70°C and condense it into a large number of extremely fine hot spots. It is a one-time treatment with natural and progressive results that last from one to two years (results vary from person to person), with ...
-
Post-treatment care after HIFU ultrasound cosmetic treatment
HIFU ultrasound machine is a non-surgical SMAS facelift procedure that uses non-invasive high energy focused ultrasound (HIFU) to stimulate the skin's natural regenerative and repair response, tightening the subcutaneous fascia layer and allowing the skin to regenerate collagen on its own, remodelling the elastic fibres and forming a strong elastic support network, thus achieving a strong ...
-
Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100 Blood Volume Diagnostic for Heart Failure Patients
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition of these hospitals contributes to the significant growth of blood volume analysis (BVA) ...
-
Bayer expands global clinical program for darolutamide in prostate cancer
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to metastatic stage Bayer further expands ...
By Bayer AG
-
New Study Confirms Daxor’s BVA-100 Volume Metric Compared to CardioMEMS Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. ...
-
Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 ...
-
Nubeqa (darolutamide) approved for additional prostate cancer indication in China
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in combination with docetaxel for the ...
By Bayer AG
-
Medicalgorithmics Announces Hiring of Medical Device Commercial Veteran James Landis as Vice President Sales and Business Development of North America
Medicalgorithmics a Warsaw Stock Exchange listed medical technology company, is boosting its sales capabilities in North America with appointment of James Landis as the new Vice President of Sales and Business Development for North America. The move is aimed at accelerating long-term growth and increasing market share in the US. James brings 20 years of extensive experience in sales and ...
-
Ionis Announces Fda Acceptance Of New Drug Application For Eplontersen For The Treatment Of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)
CARLSBAD, Calif., March 7, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The application has been given ...
-
Kardiolytics’ VCAST Technology Offers Non-Invasive and Safe Solution for Functional Evaluation of Coronary Disease, According to Recent Study in Cardiovascular Engineering and Technology
Our latest publication in Cardiovascular Engineering and Technology showcases the feasibility and functionality of our VCAST technology, a patented, AI-based medical system developed for non-invasive, clinical quantitative and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. Using a ...
-
New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA
In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in patients with NVAF and CKD, given that ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you